Table 2.
Antimicrobial activity of omadacycline against Gram-negative bacilli organisms
| Organism/organism group (number of isolates) | Number (cumulative %) of isolates at MIC (mg/L) of: | MIC50 | MIC90 | %S | %R | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | |||||
| Enterobacterales (651) | 1 (0.2) | 0 (0.2) | 11 (1.8) | 86 (15.1) | 182 (43.0) | 151 (66.2) | 101 (81.7) | 63 (91.4) | 31 (96.2) | 25 (100.0) | 2 | 8 | ||
| Ceftazidime-non-susceptible (275) | 1 (0.4) | 0 (0.4) | 5 (2.2) | 30 (13.1) | 64 (36.4) | 59 (57.8) | 51 (76.4) | 31 (87.6) | 15 (93.1) | 19 (100.0) | 2 | 16 | ||
| Tetracycline-resistant (401) | 0 (0.0) | 1 (0.2) | 40 (10.2) | 108 (37.2) | 76 (56.1) | 66 (72.6) | 54 (86.0) | 31 (93.8) | 25 (100.0) | 2 | 16 | |||
| Tigecycline-non-susceptible (55) | 0 (0.0) | 2 (3.6) | 12 (25.5) | 18 (58.2) | 23 (100.0) | 16 | 32 | |||||||
| Escherichia coli (260) | 0 (0.0) | 8 (3.1) | 60 (26.2) | 107 (67.3) | 52 (87.3) | 13 (92.3) | 8 (95.4) | 0 (95.4) | 12 (100.0) | 1 | 4 | |||
| Carbapenemase-producing (19) | 0 (0.0) | 6 (31.6) | 6 (63.2) | 4 (84.2) | 3 (100.0) | 1 | 4 | |||||||
| ESBL phenotype positive (134) a | 0 (0.0) | 6 (4.5) | 28 (25.4) | 57 (67.9) | 16 (79.9) | 9 (86.6) | 6 (91.0) | 0 (91.0) | 12 (100.0) | 1 | 8 | |||
| ESBL phenotype negative (107) a | 0 (0.0) | 2 (1.9) | 26 (26.2) | 44 (67.3) | 32 (97.2) | 1 (98.1) | 2 (100.0) | 1 | 2 | |||||
| Tetracycline-resistant (221) | 0 (0.0) | 1 (0.5) | 36 (16.7) | 99 (61.5) | 52 (85.1) | 13 (91.0) | 8 (94.6) | 0 (94.6) | 12 (100.0) | 1 | 4 | |||
| Tigecycline-non-susceptible (1) | 0 (0.0) | 1 (100.0) | ||||||||||||
| Klebsiella pneumoniae (271) | 0 (0.0) | 2 (0.7) | 21 (8.5) | 54 (28.4) | 62 (51.3) | 52 (70.5) | 44 (86.7) | 25 (95.9) | 11 (100.0) | 2 | 16 | 70.5 b,c | 13.3 b,c | |
| Carbapenemase-producing (47) | 0 (0.0) | 3 (6.4) | 0 (6.4) | 13 (34.0) | 18 (72.3) | 6 (85.1) | 5 (95.7) | 2 (100.0) | 4 | 16 | 72.3 b,c | 14.9 b,c | ||
| ESBL phenotype positive (118) a | 0 (0.0) | 4 (3.4) | 14 (15.3) | 25 (36.4) | 25 (57.6) | 28 (81.4) | 13 (92.4) | 9 (100.0) | 4 | 16 | 57.6 b,c | 18.6 b,c | ||
| ESBL phenotype negative (106) a | 0 (0.0) | 2 (1.9) | 14 (15.1) | 40 (52.8) | 24 (75.5) | 9 (84.0) | 10 (93.4) | 7 (100.0) | 1 | 8 | 84.0 b,c | 6.6 b,c | ||
| Tetracycline-resistant (127) | 0 (0.0) | 2 (1.6) | 4 (4.7) | 16 (17.3) | 31 (41.7) | 38 (71.7) | 25 (91.3) | 11 (100.0) | 8 | 16 | 41.7 b,c | 28.3 b,c | ||
| Tigecycline-non-susceptible (6) | 0 (0.0) | 2 (33.3) | 4 (100.0) | 32 | 0.0 b,c | 100.0b,c | ||||||||
| Klebsiella aerogenes (30) | 0 (0.0) | 6 (20.0) | 13 (63.3) | 4 (76.7) | 5 (93.3) | 2 (100.0) | 2 | 8 | ||||||
| Enterobacter cloacae (30) | 0 (0.0) | 3 (10.0) | 16 (63.3) | 9 (93.3) | 0 (93.3) | 0 (93.3) | 2 (100.0) | 2 | 4 | 93.3b | 6.7 b | |||
| Ceftazidime-non-susceptible (16) | 0 (0.0) | 1 (6.2) | 10 (68.8) | 4 (93.8) | 0 (93.8) | 0 (93.8) | 1 (100.0) | 2 | 4 | 93.8b | 6.2 b | |||
| Tetracycline-resistant (11) | 0 (0.0) | 1 (9.1) | 3 (36.4) | 5 (81.8) | 0 (81.8) | 0 (81.8) | 2 (100.0) | 4 | 32 | 81.8b | 18.2b | |||
| Citrobacter spp. (30) | 1 (3.3) | 0 (3.3) | 1 (6.7) | 5 (23.3) | 12 (63.3) | 5 (80.0) | 2 (86.7) | 2 (93.3) | 2 (100.0) | 1 | 8 | |||
| Tetracycline-resistant (11) | 0 (0.0) | 2 (18.2) | 3 (45.5) | 3 (72.7) | 1 (81.8) | 0 (81.8) | 2 (100.0) | 2 | 16 | |||||
| Serratia marcescens (30) | 0 (0.0) | 3 (10.0) | 21 (80.0) | 4 (93.3) | 2 (100.0) | 4 | 8 | |||||||
| Acinetobacter baumannii (198) | 8 (4.0) | 14 (11.1) | 15 (18.7) | 7 (22.2) | 16 (30.3) | 38 (49.5) | 52 (75.8) | 24 (87.9) | 18 (97.0) | 6 (100.0) | 4 | 16 | ||
| Pseudomonas aeruginosa (30) | 0 (0.0) | 1 (3.3) | 0 (3.3) | 8 (30.0) | 0 (30.0) | 21 (100.0) | 32 | 32 | ||||||
| Stenotrophomonas maltophilia (30) | 0 (0.0) | 4 (13.3) | 12 (53.3) | 11 (90.0) | 3 (100.0) | 2 | 4 | |||||||
| Moraxella catarrhalis (31) | 1 (3.2) | 25 (83.9) | 5 (100.0) | 0.12 | 0.25 | |||||||||
a ESBL: extended-spectrum β-lactamase
b Using FDA identified breakpoints for ABSSSIs
c Using FDA identified breakpoints for CABP